vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and CREATIVE REALITIES, INC. (CREX). Click either name above to swap in a different company.

CREATIVE REALITIES, INC. is the larger business by last-quarter revenue ($23.9M vs $13.5M, roughly 1.8× Assertio Holdings, Inc.). On growth, CREATIVE REALITIES, INC. posted the faster year-over-year revenue change (117.2% vs -57.9%). Over the past eight quarters, CREATIVE REALITIES, INC.'s revenue compounded faster (39.5% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

Creative Realities, Inc. is a provider of end-to-end immersive digital experience solutions, including interactive digital signage, content management software, and custom experiential design services. It primarily caters to retail, hospitality, healthcare, corporate workplace, and public sector clients across North America, helping brands enhance customer engagement and operational efficiency.

ASRT vs CREX — Head-to-Head

Bigger by revenue
CREX
CREX
1.8× larger
CREX
$23.9M
$13.5M
ASRT
Growing faster (revenue YoY)
CREX
CREX
+175.1% gap
CREX
117.2%
-57.9%
ASRT
Faster 2-yr revenue CAGR
CREX
CREX
Annualised
CREX
39.5%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASRT
ASRT
CREX
CREX
Revenue
$13.5M
$23.9M
Net Profit
$-2.0M
Gross Margin
47.9%
Operating Margin
-86.7%
1.9%
Net Margin
-8.2%
Revenue YoY
-57.9%
117.2%
Net Profit YoY
30.8%
EPS (diluted)
$-4.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
CREX
CREX
Q4 25
$13.5M
$23.9M
Q3 25
$49.5M
$10.5M
Q2 25
$29.2M
$13.0M
Q1 25
$26.5M
$9.7M
Q4 24
$32.2M
$11.0M
Q3 24
$29.2M
$14.4M
Q2 24
$31.1M
$13.1M
Q1 24
$32.4M
$12.3M
Net Profit
ASRT
ASRT
CREX
CREX
Q4 25
$-2.0M
Q3 25
$11.4M
$-7.9M
Q2 25
$-16.4M
$-1.8M
Q1 25
$-13.5M
$3.4M
Q4 24
$-2.8M
Q3 24
$-2.9M
$54.0K
Q2 24
$-3.7M
$-615.0K
Q1 24
$-4.5M
$-109.0K
Gross Margin
ASRT
ASRT
CREX
CREX
Q4 25
47.9%
Q3 25
45.3%
Q2 25
38.5%
Q1 25
45.7%
Q4 24
44.2%
Q3 24
45.6%
Q2 24
51.8%
Q1 24
46.9%
Operating Margin
ASRT
ASRT
CREX
CREX
Q4 25
-86.7%
1.9%
Q3 25
23.2%
-68.9%
Q2 25
-27.5%
-10.2%
Q1 25
-50.0%
-7.4%
Q4 24
-41.9%
-6.5%
Q3 24
-10.4%
7.9%
Q2 24
-11.6%
4.5%
Q1 24
-13.4%
-0.6%
Net Margin
ASRT
ASRT
CREX
CREX
Q4 25
-8.2%
Q3 25
23.1%
-74.5%
Q2 25
-56.0%
-13.9%
Q1 25
-51.1%
34.6%
Q4 24
-25.8%
Q3 24
-10.0%
0.4%
Q2 24
-11.8%
-4.7%
Q1 24
-13.9%
-0.9%
EPS (diluted)
ASRT
ASRT
CREX
CREX
Q4 25
$-4.54
Q3 25
$0.11
$-0.75
Q2 25
$-0.17
$-0.17
Q1 25
$-0.14
$0.32
Q4 24
$-3.28
$-0.28
Q3 24
$-0.03
$0.01
Q2 24
$-0.04
$-0.06
Q1 24
$-0.05
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
CREX
CREX
Cash + ST InvestmentsLiquidity on hand
$63.4M
$1.6M
Total DebtLower is stronger
$44.0M
Stockholders' EquityBook value
$94.0M
$21.5M
Total Assets
$267.0M
$151.0M
Debt / EquityLower = less leverage
2.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
CREX
CREX
Q4 25
$63.4M
$1.6M
Q3 25
$93.4M
$314.0K
Q2 25
$98.2M
$569.0K
Q1 25
$87.3M
$1.1M
Q4 24
$100.1M
$1.0M
Q3 24
$88.6M
$868.0K
Q2 24
$88.4M
$4.1M
Q1 24
$80.7M
$2.9M
Total Debt
ASRT
ASRT
CREX
CREX
Q4 25
$44.0M
Q3 25
$22.0M
Q2 25
$19.9M
Q1 25
$23.0M
Q4 24
$13.0M
Q3 24
$10.7M
Q2 24
$13.6M
Q1 24
$38.6M
$12.8M
Stockholders' Equity
ASRT
ASRT
CREX
CREX
Q4 25
$94.0M
$21.5M
Q3 25
$105.8M
$21.9M
Q2 25
$93.3M
$29.4M
Q1 25
$108.5M
$29.9M
Q4 24
$121.1M
$25.5M
Q3 24
$130.5M
$28.3M
Q2 24
$132.2M
$28.2M
Q1 24
$134.5M
$28.8M
Total Assets
ASRT
ASRT
CREX
CREX
Q4 25
$267.0M
$151.0M
Q3 25
$319.8M
$61.3M
Q2 25
$273.8M
$63.7M
Q1 25
$286.4M
$67.0M
Q4 24
$284.7M
$65.2M
Q3 24
$276.0M
$67.6M
Q2 24
$279.4M
$69.6M
Q1 24
$282.0M
$68.2M
Debt / Equity
ASRT
ASRT
CREX
CREX
Q4 25
2.04×
Q3 25
1.00×
Q2 25
0.68×
Q1 25
0.77×
Q4 24
0.51×
Q3 24
0.38×
Q2 24
0.48×
Q1 24
0.29×
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
CREX
CREX
Operating Cash FlowLast quarter
$-30.0M
$-4.5M
Free Cash FlowOCF − Capex
$-4.6M
FCF MarginFCF / Revenue
-19.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
CREX
CREX
Q4 25
$-30.0M
$-4.5M
Q3 25
$-4.8M
$-1.6M
Q2 25
$19.1M
$773.0K
Q1 25
$-12.5M
$-2.4M
Q4 24
$11.5M
$-1.4M
Q3 24
$-35.0K
$544.0K
Q2 24
$7.4M
$2.3M
Q1 24
$7.5M
$1.9M
Free Cash Flow
ASRT
ASRT
CREX
CREX
Q4 25
$-4.6M
Q3 25
$-1.7M
Q2 25
$672.0K
Q1 25
$-2.5M
Q4 24
$-1.4M
Q3 24
$543.0K
Q2 24
$2.3M
Q1 24
$1.9M
FCF Margin
ASRT
ASRT
CREX
CREX
Q4 25
-19.1%
Q3 25
-16.2%
Q2 25
5.2%
Q1 25
-25.2%
Q4 24
-12.5%
Q3 24
3.8%
Q2 24
17.3%
Q1 24
15.7%
Capex Intensity
ASRT
ASRT
CREX
CREX
Q4 25
0.4%
Q3 25
1.0%
Q2 25
0.8%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
ASRT
ASRT
CREX
CREX
Q4 25
Q3 25
-0.42×
Q2 25
Q1 25
-0.73×
Q4 24
Q3 24
10.07×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

CREX
CREX

Service And Other$17.3M72%
Managed Services$4.7M20%
Installation Services$1.7M7%

Related Comparisons